Skip to content

Study · Animal study (in vivo) · cynomolgus monkey · 2014

11 results

The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates.

Gotfredsen CF, Mølck AM, Thorup I, Nyborg NC, Salanti Z, Knudsen LB, Larsen MO

Diabetes7 Mar 2014Cited by 47 (Europe PMC)

PMID24608440 (opens in a new tab)DOI10.2337/db13-1087 (opens in a new tab)PepBankPUB-24608440
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In female cynomolgus monkeys, a 52-week liraglutide study showed a dose-related increase in absolute pancreas weight; males showed no such increase.

    In plain wordsIn monkeys, 52 weeks of liraglutide raised pancreas weight in females only, in a dose-related way.

    Peptide
    Liraglutide
    Outcome
    IncreaseAbsolute pancreas weight in 52-week study
    Study

    Cynomolgus monkeyn: not reported in source

    nonhuman primate toxicology studies
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 52 weeksAs given in this study (Cynomolgus monkey).

    Source sentences

    Summary
    In a 52-week study with liraglutide, a dose-related increase in absolute pancreas weight was observed in female monkeys only.
    1 context sentence
    Summary · context
    Novo Nordisk has conducted extensive toxicology studies, including data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucagon-like peptide-1 (GLP-1) receptor agonists.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In cynomolgus monkeys, liraglutide studies of 4, 13 or 87 weeks found no dose-related increase in pancreas weight.

    In plain wordsIn monkeys, liraglutide studies of 4, 13 and 87 weeks did not show a pancreas weight increase.

    Peptide
    Liraglutide
    Outcome
    No significant changeAbsolute pancreas weight in 4, 13 and 87-week studies
    Study

    Cynomolgus monkeyn: not reported in source

    nonhuman primate toxicology studies
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 4, 13 or 87 weeksAs given in this study (Cynomolgus monkey).

    Source sentences

    Summary
    Such dose-related increase was not found in studies of 4, 13, or 87 weeks' duration.
    1 context sentence
    Summary · context
    Novo Nordisk has conducted extensive toxicology studies, including data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucagon-like peptide-1 (GLP-1) receptor agonists.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In cynomolgus monkeys, no treatment-related histopathological abnormalities occurred in any of the liraglutide studies.

    In plain wordsIn monkeys, liraglutide caused no treatment-related changes in the pancreas under the microscope.

    Peptide
    Liraglutide
    Outcome
    No significant changeTreatment-related pancreatic histopathological abnormalities
    Study

    Cynomolgus monkeyn: not reported in source

    nonhuman primate toxicology studies
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No treatment-related histopathological abnormalities were observed in any of the studies.
    1 context sentence
    Summary · context
    Novo Nordisk has conducted extensive toxicology studies, including data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucagon-like peptide-1 (GLP-1) receptor agonists.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In cynomolgus monkeys, quantitative histology of the 52-week liraglutide study showed increased exocrine cell mass with normal endocrine and exocrine composition.

    In plain wordsIn monkeys, 52 weeks of liraglutide increased the mass of the pancreas digestive cells, with normal cell makeup.

    Peptide
    Liraglutide
    Outcome
    IncreaseExocrine pancreatic cell mass in 52-week study
    Study

    Cynomolgus monkeyn: not reported in source

    nonhuman primate toxicology studies
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 52 weeksAs given in this study (Cynomolgus monkey).

    Source sentences

    Summary
    Quantitative histology of the pancreas from the 52-week study showed an increase in the exocrine cell mass in liraglutide-dosed animals, with normal composition of endocrine and exocrine cellular compartments.
    1 context sentence
    Summary · context
    Novo Nordisk has conducted extensive toxicology studies, including data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucagon-like peptide-1 (GLP-1) receptor agonists.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In cynomolgus monkeys, exocrine pancreatic cell proliferation was low and comparable between liraglutide and control groups.

    In plain wordsIn monkeys, pancreas digestive cells divided at a low rate that was similar with and without liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeExocrine tissue proliferation rate
    Study

    Cynomolgus monkeyn: not reported in source

    nonhuman primate toxicology studies
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 52 weeksAs given in this study (Cynomolgus monkey).

    Source sentences

    Summary
    Proliferation rate of the exocrine tissue was low and comparable between groups.
    1 context sentence
    Summary · context
    Novo Nordisk has conducted extensive toxicology studies, including data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucagon-like peptide-1 (GLP-1) receptor agonists.
  6. 06AnimalAnimal study (in vivo)Safety outcome

    In cynomolgus monkeys, liraglutide left endocrine pancreatic cell mass unaltered.

    In plain wordsIn monkeys, liraglutide did not change the mass of the pancreas hormone-making cells.

    Peptide
    Liraglutide
    Outcome
    No significant changeEndocrine cell mass
    Study

    Cynomolgus monkeyn: not reported in source

    nonhuman primate toxicology studies
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 52 weeksAs given in this study (Cynomolgus monkey).

    Source sentences

    Summary
    Endocrine cell mass and proliferation rates were unaltered by liraglutide treatment
    1 context sentence
    Summary · context
    Novo Nordisk has conducted extensive toxicology studies, including data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucagon-like peptide-1 (GLP-1) receptor agonists.
  7. 07AnimalAnimal study (in vivo)Safety outcome

    In cynomolgus monkeys, liraglutide left endocrine pancreatic cell proliferation rates unaltered.

    In plain wordsIn monkeys, liraglutide did not change how fast the pancreas hormone-making cells divided.

    Peptide
    Liraglutide
    Outcome
    No significant changeEndocrine cell proliferation rate
    Study

    Cynomolgus monkeyn: not reported in source

    nonhuman primate toxicology studies
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 52 weeksAs given in this study (Cynomolgus monkey).

    Source sentences

    Summary
    Endocrine cell mass and proliferation rates were unaltered by liraglutide treatment.
    1 context sentence
    Summary · context
    Novo Nordisk has conducted extensive toxicology studies, including data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucagon-like peptide-1 (GLP-1) receptor agonists.
  8. 08AnimalAnimal study (in vivo)Safety outcome

    In cynomolgus monkeys, semaglutide dosed for 13 or 52 weeks caused no increase in pancreas weight.

    In plain wordsIn monkeys, semaglutide for 13 or 52 weeks did not raise pancreas weight.

    Peptide
    Semaglutide
    Outcome
    No significant changePancreas weight
    Study

    Cynomolgus monkeyn: not reported in source

    nonhuman primate toxicology studies
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 13 or 52 weeksAs given in this study (Cynomolgus monkey).

    Source sentences

    Summary
    Semaglutide showed no increase in pancreas weight and no treatment-related histopathological findings in the pancreas after 13 or 52 weeks' dosing.
    1 context sentence
    Summary · context
    Novo Nordisk has conducted extensive toxicology studies, including data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucagon-like peptide-1 (GLP-1) receptor agonists.
  9. 09AnimalAnimal study (in vivo)Safety outcome

    In cynomolgus monkeys, semaglutide dosed for 13 or 52 weeks caused no treatment-related histopathological findings in the pancreas.

    In plain wordsIn monkeys, semaglutide for 13 or 52 weeks caused no treatment-related changes in the pancreas under the microscope.

    Peptide
    Semaglutide
    Outcome
    No significant changeTreatment-related pancreatic histopathological findings
    Study

    Cynomolgus monkeyn: not reported in source

    nonhuman primate toxicology studies
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 13 or 52 weeksAs given in this study (Cynomolgus monkey).

    Source sentences

    Summary
    Semaglutide showed no increase in pancreas weight and no treatment-related histopathological findings in the pancreas after 13 or 52 weeks' dosing.
    1 context sentence
    Summary · context
    Novo Nordisk has conducted extensive toxicology studies, including data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucagon-like peptide-1 (GLP-1) receptor agonists.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 10AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Safety outcome

    In 138 nonhuman primates pooled across liraglutide and semaglutide studies, no histopathological changes in the pancreas were associated with either GLP-1 receptor agonist.

    In plain wordsIn monkeys given liraglutide or semaglutide, pooled results showed no pancreas changes under the microscope.

    Peptide
    Liraglutide
    Outcome
    No significant changePancreatic histopathological changes, pooled across liraglutide and semaglutide
    Study

    Cynomolgus monkeyn = 138

    nonhuman primate toxicology studies
    Outcome group
    Adverse events · Gastrointestinal

    Source sentences

    Summary
    Overall, results in 138 nonhuman primates showed no histopathological changes in the pancreas associated with liraglutide or semaglutide, two structurally different GLP-1 receptor agonists.
    1 context sentence
    Summary · context
    Novo Nordisk has conducted extensive toxicology studies, including data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucagon-like peptide-1 (GLP-1) receptor agonists.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 11AnimalNot a test of Semaglutide aloneAnimal study (in vivo)Safety outcome

    In 138 nonhuman primates pooled across liraglutide and semaglutide studies, no histopathological changes in the pancreas were associated with either GLP-1 receptor agonist.

    In plain wordsIn monkeys given liraglutide or semaglutide, pooled results showed no pancreas changes under the microscope.

    Peptide
    Semaglutide
    Outcome
    No significant changePancreatic histopathological changes, pooled across liraglutide and semaglutide
    Study

    Cynomolgus monkeyn = 138

    nonhuman primate toxicology studies
    Outcome group
    Adverse events · Gastrointestinal

    Source sentences

    Summary
    Overall, results in 138 nonhuman primates showed no histopathological changes in the pancreas associated with liraglutide or semaglutide, two structurally different GLP-1 receptor agonists.
    1 context sentence
    Summary · context
    Novo Nordisk has conducted extensive toxicology studies, including data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucagon-like peptide-1 (GLP-1) receptor agonists.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.